Biomarin Pharmaceutical (BMRN) Total Debt Growth (5y) (2015 - 2024)
Biomarin Pharmaceutical (BMRN) Total Debt Growth (5y) (2015 - 2024) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
| Date | Value |
|---|
| Jun 30, 2024 |
118.54% |
| Mar 31, 2024 |
41.17% |
| Jun 30, 2022 |
-11.47% |
| Mar 31, 2022 |
7.17% |
| Dec 31, 2021 |
0.81% |
| Sep 30, 2021 |
16.49% |
| Jun 30, 2021 |
-7.60% |
| Mar 31, 2021 |
-20.58% |
| Sep 30, 2020 |
31.75% |
| Jun 30, 2020 |
32.28% |
| Mar 31, 2020 |
37.19% |
| Dec 31, 2019 |
147.52% |
| Jun 30, 2019 |
70.79% |
| Mar 31, 2019 |
127.58% |
| Dec 31, 2017 |
18.09% |
| Jun 30, 2017 |
18.64% |
| Mar 31, 2017 |
14.05% |
| Sep 30, 2016 |
89.22% |
| Jun 30, 2016 |
51.06% |
| Dec 31, 2015 |
68.13% |
